NASH drug treatment development: challenges and lessons

Area of Science:

• Hepatology
• Metabolic Diseases
• Cardiovascular Health

Background:

• Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver condition globally.
• NAFLD is associated with obesity and type 2 diabetes but also affects non-obese individuals.
• NAFLD elevates the risk of cardiovascular disease, chronic kidney disease, and extrahepatic cancers.

Purpose of the Study:

• To review the current landscape of NAFLD pharmacotherapy.
• To highlight the need for treatments addressing cardiometabolic risk factors in NAFLD.
• To emphasize the importance of public awareness and stakeholder collaboration for NAFLD management.

Main Methods:

• Review of existing literature on NAFLD pharmacotherapy and clinical trials.
• Analysis of the link between NAFLD, cardiometabolic risk factors, and mortality.
• Examination of successful therapeutic strategies, such as glucose-lowering drugs.

Main Results:

• No FDA-approved pharmacotherapy currently exists for NAFLD despite extensive research.
• Cardiovascular disease is the primary cause of mortality in NAFLD patients.
• Glucose-lowering drugs show promise in managing type 2 diabetes in NAFLD patients.

Conclusions:

• Future NAFLD pharmacotherapies must integrate the management of cardiometabolic risk.
• Further development of glucose-lowering drug strategies for NAFLD is warranted.
• Increased public awareness and collaborative efforts are crucial for effective NAFLD treatment.